Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized phase 3 CLL14 study

Al‐Sawaf, Othman; Robrecht, Sandra; Zhang, Can; Olivieri, Stefano; Meng Chang, Yi; Fink, Anna‐Maria; Tausch, Eugen; Schneider, Christof; Ritgen, Matthias; Kreuzer, Karl‐Anton; Sivcheva, Liliya; Utoft Niemann, Carsten; P. Schwarer, Anthony; Loscertales, Javier; Weinkove, Robert; Strumberg, Dirk; Kilfoyle, Allanah; S. Manzoor, Beenish; Jawaid, Dureshahwar; Emechebe, Nnadozie; Devine, Jacob; Boyer, Michelle; Diana Runkel, Eva; Eichhorst, Barbara; Stilgenbauer, Stephan; Jiang, Yanwen; Hallek, Michael; Fischer, Kirsten

doi:10.1182/blood.2024024631

Public

Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized phase 3 CLL14 study

Published in Blood • Jul 31, 2024

Authors:

Othman Al‐Sawaf

Sandra Robrecht

Can Zhang

Abstract

ABSTRACT: In the CLL14 study, patients with previously untreated chronic lymphocytic leukemia (CLL) and coexisting conditions were randomized to 12 cycles of venetoclax-obinutuzumab (Ven-Obi, n = 216) or chlorambucil-obinutuzumab (Clb-Obi, n = 216). Progression-free survival (PFS) was the primary en...

Subject

Medicine

Obinutuzumab

Ven

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!